Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2025 16:05 ET | Source: Tempest Therapeutics

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
April 21, 2025 08:00 ET | Source: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
April 09, 2025 16:30 ET | Source: Tempest Therapeutics

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug...
March 27, 2025 16:10 ET | Source: Tempest Therapeutics

Tempest Reports Year End 2024 Financial Results and Provides Business Update

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support...
March 25, 2025 16:30 ET | Source: Tempest Therapeutics

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
March 13, 2025 08:00 ET | Source: Tempest Therapeutics

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
February 10, 2025 08:00 ET | Source: Tempest Therapeutics

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE,...
February 07, 2025 16:30 ET | Source: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
January 06, 2025 08:00 ET | Source: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
December 06, 2024 16:30 ET | Source: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Next Page keyboard_arrow_right